Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Arnold G. Werschky III who wrote (1156)	4/15/1998 10:11:00 AM
From: gates jr	Read Replies (1) \| Respond to of 9523

Will PFE correct from these levels? I guess anything is possible. However, this company is peaking. Earnings were in line with estimates for last quater. That did not reflect the impact that viagra will have on this company. Furthermore, other new products will hit the market this year as well as expected continued strong sales for their current products. There is only good news coming from this company, so any weakness in the stock price only represents what I feel is a golden opportunity to accumulate more stock, which in the long run should continue it's upward trend. good luck to all

To: Arnold G. Werschky III who wrote (1156)	4/15/1998 10:46:00 AM
From: James Baker	Respond to of 9523

Arnold: Lipitor sales Agreement? You'll have to excuse me, I'm a little bit hazy on the impact of Lipitor sales to Pfizer. Did they not develop the drug? If there is a licensing agreement....does anyone know what it is?>>>>>>>> Arnold, PFE did NOT develop Lipitor but Warner Lambert did and WLA owns the patent. PFE is co-marketing Lipitor and gets a cut on the sales. The exact agreement details have never been revealed and PFE detailed earnings report chooses to lump their alliance revenue together so that there is no way to even figure it out for sure. Jim